Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atorvastatin + fenofibrate
- Development stage
- Phase 4
- Lead developer
- SSK Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
STATIN-AF10 is a fixed-dose combination of atorvastatin and fenofibrate marketed by SSK Pharma. Atorvastatin is an HMG-CoA reductase inhibitor (statin) that reduces cholesterol synthesis in the liver, lowering low-density lipoprotein cholesterol (LDL-C) and triglycerides while increasing high-density lipoprotein cholesterol (HDL-C). Fenofibrate is a fibric acid derivative (fibrate) that activates peroxisome proliferator-activated receptor alpha (PPAR-alpha), leading to increased lipolysis and elimination of triglyceride-rich particles from plasma. Together, this combination is used to treat mixed dyslipidemia, hypercholesterolemia, and hypertriglyceridemia, and to reduce the risk of cardiovascular events such as heart attack and stroke.
- Brand names
- Atorbis FAtorcin-F10Atorcin-F-10Atorcin-F 10Atorfit MaxAtorlip-FAtorva TGAtorvus FFibatorLipicard AVLipikind-FSTATIN-AF10STATIN-AF-10STATIN-AF 10Tonact-TG
- Other names
- atorvastatin and fenofibrateatorvastatin/fenofibratefenofibrate + atorvastatinfenofibrate and atorvastatinfenofibrate/atorvastatin
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)PPARA (Peroxisome proliferator-activated receptor alpha)
Beyond the preview
Go deeper on atorvastatin + fenofibrate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atorvastatin + fenofibrate.